Pune, India – The global Oncology Companion Diagnostic Market is witnessing significant growth as precision medicine continues to transform cancer diagnosis and treatment. Increasing adoption of biomarker testing, molecular diagnostics, and targeted therapies is enabling healthcare providers to deliver more personalized treatment strategies, improving patient outcomes while supporting advances in oncology research.

According to Quintile Reports, the global Oncology Companion Diagnostic Market was valued at USD 5.44 billion in 2026 and is projected to reach USD 14.59 billion by 2035, registering a CAGR of 10.37% during the forecast period. The market is expanding due to growing cancer incidence, continuous technological innovation, and increasing investment in precision healthcare.

Companion diagnostics have become an essential component of modern oncology by helping clinicians identify patients who are most likely to benefit from specific therapies. Advanced technologies such as Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), and Fluorescence In Situ Hybridization (FISH) are improving diagnostic accuracy and supporting personalized treatment decisions.

The market continues to benefit from the increasing global burden of cancer, expanding pharmaceutical collaborations, and supportive regulatory initiatives that encourage the co-development of targeted therapies and companion diagnostic tests. At the same time, innovations in artificial intelligence, genomic profiling, and liquid biopsy technologies are creating new opportunities for healthcare providers, diagnostic laboratories, and biotechnology companies.

Despite strong growth prospects, the industry faces challenges including high testing costs, reimbursement limitations, regulatory complexity, and the need for standardized biomarker validation. Addressing these issues will be essential to expand patient access to advanced diagnostic solutions across global healthcare systems.

Regionally, North America remains the leading market owing to its advanced healthcare infrastructure, significant oncology research funding, and supportive regulatory environment. Meanwhile, the Asia-Pacific region is expected to record the fastest growth, driven by increasing healthcare investment, rising cancer prevalence, and expanding adoption of genomic testing technologies.

Leading companies operating in the Oncology Companion Diagnostic Market include Roche Diagnostics, Thermo Fisher Scientific, Agilent Technologies, Illumina, Qiagen, Myriad Genetics, Foundation Medicine, Abbott Laboratories, Guardant Health, Sysmex Corporation, Leica Biosystems, and Adaptive Biotechnologies. These organizations continue to invest in innovative molecular diagnostic platforms, precision oncology solutions, and strategic collaborations to strengthen their market position.

As precision medicine continues to reshape the future of cancer care, the Oncology Companion Diagnostic Market is expected to play an increasingly important role in improving clinical outcomes and supporting the development of next-generation targeted therapies.

For organizations seeking comprehensive market intelligence, the report provides detailed analysis of market size, forecasts, competitive landscape, regional insights, technological trends, and growth opportunities to support strategic decision-making.

Read the Full Report Here for in-depth analysis and forecasts : https://www.quintilereports.com/industry-report/1086-oncology-companion-diagnostic-market/